Found: 22
Select item for more details and to access through your institution.
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 2, p. 493, doi. 10.1007/s00432-019-03077-w
- By:
- Publication type:
- Article
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1307545
- By:
- Publication type:
- Article
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Plasma levels of VEGF‐A and VCAM‐1 as predictors of drug‐induced hypertension in patients treated with VEGF pathway inhibitors.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 9, p. 4171, doi. 10.1111/bcp.15356
- By:
- Publication type:
- Article
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5451, doi. 10.3390/cancers15225451
- By:
- Publication type:
- Article
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4683, doi. 10.3390/cancers15194683
- By:
- Publication type:
- Article
Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging.
- Published in:
- Cancers, 2023, v. 15, n. 8, p. 2200, doi. 10.3390/cancers15082200
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 4974, doi. 10.3390/cancers14204974
- By:
- Publication type:
- Article
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
- Published in:
- PLoS ONE, 2020, v. 15, n. 9, p. 1, doi. 10.1371/journal.pone.0239439
- By:
- Publication type:
- Article
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
ShorTrip Trial: A Prospective, Multicentric Phase H Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 3, p. 339, doi. 10.1016/j.clcc.2023.06.002
- By:
- Publication type:
- Article
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
- Published in:
- Clinical Colorectal Cancer, 2021, v. 20, n. 4, p. 314, doi. 10.1016/j.clcc.2021.07.001
- By:
- Publication type:
- Article
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
- Published in:
- 2018
- By:
- Publication type:
- journal article
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 302, doi. 10.1002/onco.13642
- By:
- Publication type:
- Article
HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 10, p. 1395, doi. 10.1634/theoncologist.2018-0785
- By:
- Publication type:
- Article
Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
- Published in:
- Oncologist, 2018, v. 23, n. 10, p. 1178, doi. 10.1634/theoncologist.2017-0573
- By:
- Publication type:
- Article
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2016, v. 21, n. 8, p. 988, doi. 10.1634/theoncologist.2016-0084
- By:
- Publication type:
- Article
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-39525-3
- By:
- Publication type:
- Article